HCW Biologics prices $1.5 million private placement with existing investor
The company will use proceeds to fund clinical work on HCW9302 and early-stage development of two other pipeline candidates.
SEC filing
Latest
6 stories
Thursday, September 24
Tuesday, September 8
HCW Biologics signs exclusive distribution deal with Akron Biotech for HCW11-006
The agreement covers a five-year, worldwide (excluding China) distribution arrangement for HCW11-006 as a CAR-T manufacturing reagent, with closing set for no later than November 30, 2026.
SEC filing
Thursday, August 20
HCW Biologics S-1 flags new Nasdaq market-value rule and SEC stay on its approval
The S-1 resale filing adds detail on a proposed Nasdaq market-value listing standard that the SEC approved and then paused pending review.
SEC filing
Friday, August 14
HCW Biologics reports Q2 2026 results, alopecia data and going concern doubt
The company said preliminary Phase 1 data show SALT score improvements for HCW9302 in alopecia areata, with full data expected in Q4 2026, while flagging substantial doubt about its ability to continue as a going.
SEC filing
Thursday, August 6
HCW Biologics reports $1.6 million private securities sale in SEC filing
The Miramar, Florida biotech disclosed a Regulation D offering with a first sale date of July 29, 2026, sold in full to four investors.
SEC filing
Wednesday, July 29
HCW Biologics prices $1.6 million private placement offering
The Nasdaq-listed company said it will use proceeds to fund clinical trials for HCW9302 and advance two pipeline candidates, with insiders including its CEO among the investors.
SEC filing